Aberrant Promoter Hypermethylation of PBRM1, BAP1, SETD2, KDM6A and Other Chromatin-modifying Genes is Absent or Rare in Clear Cell RCC

Overview

Journal Epigenetics

Specialty Genetics

Date 2013 May 7

PMID 23644518

Citations 28

Authors

Ilsiya Ibragimova

Marie E Maradeo

Essel Dulaimi

Paul Cairns

Affiliations

Soon will be listed here.

Abstract

Recent sequencing studies of clear cell (conventional) renal cell carcinoma (ccRCC) have identified inactivating point mutations in the chromatin-modifying genes PBRM1, KDM6A/UTX, KDM5C/JARID1C, SETD2, MLL2 and BAP1. To investigate whether aberrant hypermethylation is a mechanism of inactivation of these tumor suppressor genes in ccRCC, we sequenced the promoter region within a bona fide CpG island of PBRM1, KDM6A, SETD2 and BAP1 in bisulfite-modified DNA of a representative series of 50 primary ccRCC, 4 normal renal parenchyma specimens and 5 RCC cell lines. We also interrogated the promoter methylation status of KDM5C and ARID1A in the Cancer Genome Atlas (TCGA) ccRCC Infinium data set. PBRM1, KDM6A, SETD2 and BAP1 were unmethylated in all tumor and normal specimens. KDM5C and ARID1A were unmethylated in the TCGA 219 ccRCC and 119 adjacent normal specimens. Aberrant promoter hypermethylation of PBRM1, BAP1 and the other chromatin-modifying genes examined here is therefore absent or rare in ccRCC.

Citing Articles

Genetic study of the and genes in renal cell carcinoma patients.

Kiatprungvech N, Sangkum P, Malinee R, Sommaluan S, Korkiatsakul V, Worawichawong S Pract Lab Med. 2024; 40:e00410.

PMID: 38867760 PMC: 11167386. DOI: 10.1016/j.plabm.2024.e00410.

The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer.

Nguyen V, Tessema M, Weissman B Cancer Treat Res. 2023; 190:211-244.

PMID: 38113003 DOI: 10.1007/978-3-031-45654-1_7.

Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell renal cell carcinoma.

Gui Z, Du J, Wu N, Shen N, Yang Z, Yang H BMC Cancer. 2023; 23(1):649.

PMID: 37438709 PMC: 10337188. DOI: 10.1186/s12885-023-11150-4.

Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome.

El Khoury L, Pan X, Hlady R, Wagner R, Shaikh S, Wang L Clin Epigenetics. 2023; 15(1):71.

PMID: 37120552 PMC: 10149001. DOI: 10.1186/s13148-023-01471-3.

Bioinformatic analysis identifying FGF1 gene as a new prognostic indicator in clear cell Renal Cell Carcinoma.

Zhang X, Wang Z, Zeng Z, Shen N, Wang B, Zhang Y Cancer Cell Int. 2021; 21(1):222.

PMID: 33865387 PMC: 8052755. DOI: 10.1186/s12935-021-01917-9.

References

Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R . Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics. 2011; 1(1):177-200. DOI: 10.2217/epi.09.14. View

Takai D, Jones P . Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A. 2002; 99(6):3740-5. PMC: 122594. DOI: 10.1073/pnas.052410099. View

Grunau C, Clark S, Rosenthal A . Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res. 2001; 29(13):E65-5. PMC: 55789. DOI: 10.1093/nar/29.13.e65. View

Herman J, Latif F, Weng Y, Lerman M, Zbar B, Liu S . Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994; 91(21):9700-4. PMC: 44884. DOI: 10.1073/pnas.91.21.9700. View

Sandovici I, Leppert M, Hawk P, Suarez A, Linares Y, Sapienza C . Familial aggregation of abnormal methylation of parental alleles at the IGF2/H19 and IGF2R differentially methylated regions. Hum Mol Genet. 2003; 12(13):1569-78. DOI: 10.1093/hmg/ddg167. View

Smits K, Schouten L, van Dijk B, Hulsbergen-van de Kaa C, Wouters K, Oosterwijk E . Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis. Clin Cancer Res. 2008; 14(3):782-7. DOI: 10.1158/1078-0432.CCR-07-1753. View

Bott M, Brevet M, Taylor B, Shimizu S, Ito T, Wang L . The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011; 43(7):668-72. PMC: 4643098. DOI: 10.1038/ng.855. View

Maradeo M, Cairns P . Translational application of epigenetic alterations: ovarian cancer as a model. FEBS Lett. 2011; 585(13):2112-20. PMC: 3129436. DOI: 10.1016/j.febslet.2011.03.016. View

Lohr J, Stojanov P, Lawrence M, Auclair D, Chapuy B, Sougnez C . Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012; 109(10):3879-84. PMC: 3309757. DOI: 10.1073/pnas.1121343109. View

10.

Wiegand K, Shah S, Al-Agha O, Zhao Y, Tse K, Zeng T . ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363(16):1532-43. PMC: 2976679. DOI: 10.1056/NEJMoa1008433. View

11.

Herman J, Umar A, Polyak K, Graff J, Ahuja N, Issa J . Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998; 95(12):6870-5. PMC: 22665. DOI: 10.1073/pnas.95.12.6870. View

12.

Tsuchiya K, Greally J, Yi Y, Noel K, Truong J, Disteche C . Comparative sequence and x-inactivation analyses of a domain of escape in human xp11.2 and the conserved segment in mouse. Genome Res. 2004; 14(7):1275-84. PMC: 442142. DOI: 10.1101/gr.2575904. View

13.

Linehan W, Srinivasan R, Schmidt L . The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010; 7(5):277-85. PMC: 2929006. DOI: 10.1038/nrurol.2010.47. View

14.

Cunningham J, Christensen E, Tester D, Kim C, Roche P, Burgart L . Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998; 58(15):3455-60. View

15.

Morin R, Mendez-Lago M, Mungall A, Goya R, Mungall K, Corbett R . Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011; 476(7360):298-303. PMC: 3210554. DOI: 10.1038/nature10351. View

16.

Dulaimi E, de Caceres I, Uzzo R, Al-Saleem T, Greenberg R, Polascik T . Promoter hypermethylation profile of kidney cancer. Clin Cancer Res. 2004; 10(12 Pt 1):3972-9. DOI: 10.1158/1078-0432.CCR-04-0175. View

17.

Costa V, Henrique R, Ribeiro F, Pinto M, Oliveira J, Lobo F . Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer. 2007; 7:133. PMC: 1940017. DOI: 10.1186/1471-2407-7-133. View

18.

Li Y, Zhu J, Tian G, Li N, Li Q, Ye M . The DNA methylome of human peripheral blood mononuclear cells. PLoS Biol. 2010; 8(11):e1000533. PMC: 2976721. DOI: 10.1371/journal.pbio.1000533. View

19.

Veigl M, Kasturi L, Olechnowicz J, Ma A, Lutterbaugh J, Periyasamy S . Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A. 1998; 95(15):8698-702. PMC: 21139. DOI: 10.1073/pnas.95.15.8698. View

20.

Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View